Medical Doctor Program year 2024 Reported 2022–2024 Source: CMS Open Payments, 2026 publication

William Denk

Pain Medicine Cheyenne, WY Medical Doctor

NPI 1407340771 CMS profile 4739314

2301 House Ave Ste 201, Cheyenne, WY 82001

Open in the dashboard

General payments

$5,296

24 records reported · program years 2022–2024

Research payments

$0

Paid to them · None reported · program years 2022–2024

Ownership & investment interest

$0

None reported

Through program year 2024, William Denk of Cheyenne, WY is reported in the CMS Open Payments database as having received $5,296 across 24 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $14 1
2023 General $1,242 11
2022 General $4,040 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Denk
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to William Denk were reported at $0. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year William Denk Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $0 $399 $112–$1,219 $132
2022 $4,040 $455 $137–$1,484 $149
2023 $1,242 $484 $128–$1,495 $160
2024 $14 $498 $131–$1,540 $164
2025 $0 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2022–2024
  1. Medtronic, Inc. $4,882 18 payments
  2. SPR Therapeutics, Inc $400 5 payments
  3. Abbott Laboratories $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2024
  1. Grant $2,500 1 payment
  2. Travel and Lodging $1,952 8 payments
  3. Food and Beverage $844 15 payments
Products named General payments · program years 2022–2024
  1. SYNCHROMEDII $2,500 1 payment
  2. INTELLIS ADAPTIVESTIM $2,382 17 payments
  3. SPRINT PNS System $400 5 payments
  4. ETERNA $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

348

Median for Pain Management: 951

Drug cost

$9,778

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 86 $3,987
Buprenorphine Generic 17 $2,479
Baclofen Generic 100 $1,642
Gabapentin Generic 63 $1,025
Duloxetine Hcl Generic 23 $384
Cyclobenzaprine Hcl Generic 13 $153
Tramadol Hcl Generic 27 $65
Meloxicam Generic 19 $43

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$65,682

Of which drugs: $135

Medicare patients

201

Average age 73

Services billed

1,995

125 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Depression 29%
Diabetes 22%
Chronic kidney disease 20%
COPD 18%
Osteoporosis 17%
Ischemic heart disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 19 1,200 $113

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

24 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record